Insight Molecular Diagnostics Price to Sales Ratio 2014-2026 | IMDX
Historical PS ratio values for Insight Molecular Diagnostics (IMDX) over the last 10 years. The current P/S ratio for Insight Molecular Diagnostics as of September 14, 2026 is .
| Insight Molecular Diagnostics P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2026-09-15 | 4.02 | 75.96 | |
| 2026-06-30 | 5.90 | $0.05 | 111.49 |
| 2026-03-31 | 3.28 | $0.06 | 52.40 |
| 2025-12-31 | 7.50 | $0.14 | 51.77 |
| 2025-09-30 | 3.32 | $0.22 | 15.01 |
| 2025-06-30 | 3.02 | $0.22 | 13.64 |
| 2025-03-31 | 3.06 | $0.21 | 14.34 |
| 2024-12-31 | 2.38 | $0.15 | 15.71 |
| 2024-09-30 | 2.85 | $0.08 | 36.17 |
| 2024-06-30 | 2.95 | $0.12 | 24.11 |
| 2024-03-31 | 2.93 | $0.17 | 17.08 |
| 2023-12-31 | 2.50 | $0.20 | 12.50 |
| 2023-09-30 | 3.12 | $0.21 | 14.97 |
| 2023-06-30 | 4.60 | $0.17 | 27.41 |
| 2023-03-31 | 7.08 | $0.15 | 46.43 |
| 2022-12-31 | 6.42 | $0.19 | 34.69 |
| 2022-09-30 | 14.60 | $-0.30 | 0.00 |
| 2022-06-30 | 18.00 | $-0.10 | 0.00 |
| 2022-03-31 | 29.80 | $0.31 | 95.04 |
| 2021-12-31 | 43.40 | $0.50 | 85.96 |
| 2021-09-30 | 71.20 | $1.09 | 65.05 |
| 2021-06-30 | 114.80 | $1.04 | 109.91 |
| 2021-03-31 | 103.80 | $0.64 | 163.32 |
| 2020-12-31 | 47.80 | $0.37 | 130.23 |
| 2020-09-30 | 27.80 | $0.21 | 130.08 |
| 2020-06-30 | 38.20 | $0.05 | 785.21 |
| 2020-03-31 | 49.00 | $0.01 | 0.00 |
| 2019-12-31 | 45.00 | 0 | 0.00 |
| 2019-09-30 | 42.00 | 0 | 0.00 |
| 2019-06-30 | 49.80 | 0 | 0.00 |
| 2019-03-31 | 79.00 | 0 | 0.00 |
| 2018-12-31 | 27.60 | 0 | 0.00 |
| 2018-09-30 | 50.00 | 0 | 0.00 |
| 2018-06-30 | 51.00 | 0 | 0.00 |
| 2018-03-31 | 42.00 | 0 | 0.00 |
| 2017-12-31 | 93.00 | 0 | 0.00 |
| 2017-09-30 | 151.00 | 0 | 0.00 |
| 2017-06-30 | 104.00 | 0 | 0.00 |
| 2017-03-31 | 119.00 | 0 | 0.00 |
| 2016-12-31 | 141.00 | 0 | 0.00 |
| 2016-09-30 | 100.80 | 0 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.132B | $0.004B |
| Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $43.014B | 42.92 |
| Tempus AI (TEM) | United States | $11.225B | 0.00 |
| 10x Genomics (TXG) | United States | $9.135B | 0.00 |
| Hinge Health (HNGE) | United States | $7.649B | 73.48 |
| Hims & Hers Health (HIMS) | United States | $6.722B | 0.00 |
| Doximity (DOCS) | United States | $4.704B | 29.00 |
| Heartflow (HTFL) | United States | $4.308B | 0.00 |
| IRhythm Holdings (IRTC) | United States | $3.782B | 249.39 |
| Clover Health Investments (CLOV) | United States | $2.709B | 0.00 |
| Privia Health (PRVA) | United States | $2.667B | 99.43 |
| Inspire Medical Systems (INSP) | United States | $2.149B | 32.74 |
| Butterfly Network (BFLY) | United States | $1.973B | 0.00 |
| Schrodinger (SDGR) | United States | $1.532B | 0.00 |
| Omnicell (OMCL) | United States | $1.524B | 21.76 |
| Azenta (AZTA) | United States | $1.404B | 76.29 |
| Enovis (ENOV) | United States | $1.051B | 5.44 |
| Talkspace (TALK) | United States | $0.879B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.659B | 0.00 |
| Phreesia (PHR) | United States | $0.647B | 34.73 |
| Claritev (CTEV) | United States | $0.618B | 0.00 |
| Veradigm (MDRX) | United States | $0.593B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.568B | 0.00 |
| Evolent Health (EVH) | United States | $0.464B | 0.00 |
| Carlsmed (CARL) | United States | $0.419B | 0.00 |
| Senseonics Holdings (SENS) | United States | $0.370B | 0.00 |
| CapsoVision (CV) | United States | $0.326B | 0.00 |
| Standard BioTools (LAB) | United States | $0.273B | 0.00 |
| American Well (AMWL) | United States | $0.230B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.144B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.137B | 0.00 |
| CareCloud (CCLD) | United States | $0.089B | 6.53 |
| Pulmonx (LUNG) | United States | $0.085B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.065B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.062B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.060B | 0.00 |
| Outset Medical (OM) | United States | $0.059B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.050B | 0.00 |
| Precipio (PRPO) | United States | $0.049B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.035B | 0.00 |
| 111 (YI) | China | $0.031B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.026B | 0.00 |
| HeartBeam (BEAT) | United States | $0.023B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| HeartSciences (HSCS) | United States | $0.014B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.011B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.010B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.009B | 0.00 |
| ITonic Holdings (ITOC) | China | $0.005B | 0.00 |
| DataMeds AI (MEDS) | United States | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| PROFUSA (PFSA) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |
| Zhongchao (ZCMD) | China | $0.001B | 0.00 |
| TruBridge (TBRG) | United States | $0.000B | 0.00 |